FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter) Delaware 47-5461709 (State or other juris ...

1 Corporate Presentation June 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and a ...

Confidential Corporate Presentation May 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of cur ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - Senior Vice President Conference Call Participants Joseph Schwartz - SVB Leerink Eliana Merle - Cantor Fitzgerald Carter Gould - Barclays Tyler Van Buren - Piper Sandler David Hoang - SMBC Operator Ladies and gentlemen, thank you for standing by ...

For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant as specified in its charter) Delaware 47-5461709 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter) Delaware 47-5461709 (State or other jurisdiction of incorporation or organization) 3013 Science P ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujrathi - Co-founder & Chief Executive Officer Jakob Dupont - Chief Medical Officer Luisa Salter-Cid - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good afternoon, and welcome to the Gossamer Bio Third Quarter 2019 Earnings Call. Today's call will feature updates from Gossamer Bio's management team ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter) Delaware 47-5461709 (State or other jurisdiction of incorporation or organization) 3013 Science Park Road San Diego, California 92121 (Address of principal executive offices) (Zip Co ...

Confidential Corporate Presentation Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder, President, CEO & Director Jakob Dupont - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good day, ladies and gentlemen, and welcome to the Gossamer Bio Second Quarter 2019 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. I'd now like to turn the conferen ...